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Abstract: Clostridium tetani is the etiological agent of tetanus, a life-threatening bacterial infection.
The most efficient protection strategy against tetanus is a vaccination with the C. tetani neurotoxin,
which is inactivated by formaldehyde-crosslinking. Since we assumed that besides the tetanus toxin,
other proteins of C. tetani may also be present in toxoid preparations, we analyzed commercially
available vaccines from different countries in respect to their protein content using mass spectrometry.
In total 991 proteins could be identified in all five analyzed vaccines, 206 proteins were common in all
analyzed vaccines and 54 proteins from the 206 proteins were potential antigens. The additionally
present proteins may contribute at least partially to protection against C. tetani infection by supporting
the function of the vaccine against the devastating effects of the tetanus toxin indirectly. Two different
label-free protein quantification methods were applied for an estimation of protein contents. Similar
results were obtained with a Total Protein Approach (TPA)-based method and Protein Discoverer 2.2
software package based on the minora algorithm. Depending on the tetanus toxoid vaccine and the
quantification method used, tetanus neurotoxin contributes between 14 and 76 % to the total C. tetani
protein content and varying numbers of other C. tetani proteins were detected.
Keywords: Clostridium tetani; label-free quantification; neurotoxin; proteomics; tetanospasmin; vaccination
1. Introduction
Toxigenic strains of Clostridium tetani can cause tetanus, a life-threatening bacterial infection.
Spores of this obligate anaerobic, saprophytic bacterium, which preferentially lives in warm and
moist habitats, are present in environments all over the world and may enter the human body via
contamination of wounds. These may be the result of injuries in case of adults or children or occur in
case of newborns during birth when the umbilical cord is cut (neonatal tetanus). Under anaerobic
conditions in dirt-contaminated wounds, poorly blood supplied or necrotic tissue, the spores may
germinate and the vegetative cells can proliferate and produce exotoxin. Tetanospasmin, the extremely
potent neurotoxin of C. tetani, blocks inhibitory neurotransmitters of the central nervous system,
preventing relaxation of muscles and leading to muscle rigidity and spastic paralysis that are typical
for tetanus [1]. Based on the frequent abundance of C. clostridium spores in the environment and a
high fatality rate, which is almost 100% in case of lacking immune protection and intensive medical
treatment, tetanus is a serious threat for human health. However, it can easily be prevented by
vaccination with tetanus toxoid vaccine, which was already introduced in 1924, making it one of the
oldest used vaccines (for review, see reference [2]).
Tetanus vaccine production is based on a C. tetani strain, designated as the “Harvard strain”,
which was initially collected in the United States of America in the 1920s and subsequently distributed
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among scientists and vaccine producers worldwide [3]. In short, the bacteria are grown in liquid broth
under anaerobic conditions, the toxin secreted by C. tetani is separated from bacteria and medium
components using a filtration step and subsequently it is inactivated by cross-linking for four to six
weeks or longer at 37 ◦C using 40% formaldehyde [4]. The resulting inactivated, crosslinked toxoid
preparation may be used as a single antigen vaccine or in combination with other proteins to protect
against diphtheria, pertussis and other vaccine-preventable diseases. Furthermore, tetanus toxoid is
applied as a carrier protein in a number of conjugate vaccines. Applied either alone, in combination
with other components as in diphtheria toxoid and tetanus toxoid (DT) vaccines or diphtheria, pertussis,
and tetanus (DPT) vaccines or in co-administration with other vaccines, it is considered as safe and
only mild local reactions may be expected [2,4].
Since it is well-known that bacteria may secrete different proteins into the medium during growth
and also cell lysis may occur during cultivation in bio-reactors (e.g., [5–9]), we assumed that besides the
tetanus toxin other proteins of C. tetani may also be present in toxoid preparations. To investigate this
hypothesis, we used a recently developed protocol [10] to purify proteins from commercially available
vaccines, reverse the formaldehyde cross-linking and analyze the protein inventory by tryptic digest
and mass spectrometry.
2. Materials and Methods
2.1. Preparation of Vaccines Used in This Study
Commercially available diphtheria toxoid and tetanus toxoid (DT) vaccines used for proteome
analyses are shown in Table 1. Since the protein content of the vaccine analyzed in this study was
considered low, 10 vaccine doses (0.5 mL each) were pooled and precipitated by addition of 10%
(w/v) trichloroacetic acid (TCA) and incubation at 4 ◦C for 16 h to get a concentrated sample for mass
spectrometry analysis [11]. After incubating over-night at 4 ◦C the samples were centrifuged at 8000 x g
for 30 min at 4 ◦C. The precipitated proteins were dried on ice and resuspended in rehydration buffer (2%
sodium deoxycholate, 10 mM dithiothreitol (DTT), 50 mM Tris, pH 8.0). To reverse the formaldehyde
cross-linking of the inactivated toxins, the samples were incubated for 20 min at 95 ◦C [12]. The protein
amount one vaccine dose was determined using a spectrophotometer (NanoDrop LITE, Thermo Fisher
Scientific, Bremen, Germany) at 280 nm.
Table 1. Vaccine samples analyzed in this study. The concentrations of the active components are
shown in flocculation units (Lf) *1, international units (I.U.) *2 and binding units (BU) *3.
Origin Company Active components
Brazil Butanan Institute Tetanus toxoid ≥ 25 Lf/mLDiphtheria toxoid ≥ 2 Lf/mL
Bulgaria InterVax for BB-NCIPD Tetanus toxoid ≥ 20 Lf/mLDiphtheria toxoid ≥ 30 Lf/mL
Germany GlaxoSmithKline (GSK) Tetanus toxoid ≥ 20 I.U.Diphtheria toxoid ≥ 2 I.U.
India Biological E (BE) Tetanus toxoid ≥ 20 I.U.Diphtheria toxoid ≥ 2 I.U.
Russia Microgen Tetanus toxoid ≥ 5 BU/mLDiphtheria toxoid ≥ 5 Lf/mL
*1: Flocculation units (Lf) are defined as the equivalent of toxin to one unit of standard antitoxin or the amount of
toxin that flocculates one unit of an international reference antitoxin [13,14]. *2: International units (I.U.) are defined
as a certain weight of the international standard for antitoxin [15] and are equal to the corresponding amount of
toxin. *3: Binding units (BU) correspond to the amount of tetanus toxoid to bind directly or compete with tetanus
antibody [16] and, therefore, are equal to Lf or I.U.
2.2. Tryptic Digest and C18 Clean up
About 10 µg soluble proteins prepared from the vaccine samples (see above) were transferred
to 10 kDa vivacon 500 membrane filters and the flow-through was discarded by centrifugation for
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30 min at 12,000 × g. The tryptic digest of the prepared vaccines samples occurred within the modified
Filter Aided Sample Preparation (FASP) protocol [11,17]. The proteins were reduced by addition
of 200 µl of reduction buffer (25 mM DTT, 8 M urea, 50 mM triethylammonium bicarbonate buffer
(TEAB)) for 30 min at 37 ◦C. Alkylation of sulfhydryl groups were carried out with 200 µl alkylation
buffer (25 mM chloroacetamide (CAA), 8 M urea, 50 mM TEAB) for additional 30 min on a shaker at
600 rpm in the dark. The proteins were subsequently washed with 300 µl of 8 M urea in 50 mM TEAB
followed by another washing step with 200 µL 6 M urea in 50 mM TEAB. Afterwards 0.5 µg mass
spectrometry grade LysC endopeptidase was added onto the filter unit and incubated on a shaker at
37 ◦C and 600 rpm for 3 h, followed by a second digest with 1 µg trypsin and 250 µL dilution buffer
(50 mM TEAB) to reach a final concentration of 1 M urea. The sample was incubated over-night at
37 ◦C at 600 rpm on a shaker. Peptides were then collected by centrifugation at 12,000 × g for 20 min.
For acidification of the peptide solution 20 µL of 10% trifluoroacetic acid (TFA) was added to reach a
final concentration of 0.5% TFA. To desalt the peptides a clean-up with C18 stage tips were performed.
Prior to LC-MS/MS analysis, peptides were vacuum dried and resuspended in 0.1% trifluoroacetic acid
(TFA) [8].
2.3. Mass Spectrometry
For mass spectrometric analyses peptides (250 or 2500 ng, respectively) were loaded onto a
nanoflow Ultimate 3000 HPLC (Dionex, Sunnyvale, CA, USA). Separation was carried out using an
EASY-Spray column (Thermo Fisher Scientific; C18 with 2 µm particle size, 50 cm × 75 µm) with a flow
rate of 200 nl min−1 and increasing acetonitrile concentrations over 120 min. Method duration including
equilibration and column wash was in total 160 min. All samples were analyzed on an Orbitrap
Fusion mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The mass spectrometer
was operating with 2000 V spray voltage, 275 ◦C transfer tube temperature, 300–2000 (m/z) scan
range for the MS 1 detection in the Orbitrap, a maximum injection time of 50 ms, an automatic gain
control (AGC) target of 400,000 and an Orbitrap resolution of 120.000. The most intense ions were
selected for collision-induced dissociation with collision energy of 35%. For ion trap detection a
maximum injection time of 250 ms and an AGC target of 100 were set [8,17]. Resulting raw data
files were analyzed using the Clostridium tetani E88 database (Proteome Id: UP000001412) and the C.
diphtheriae ATCC 700971/NCTC 13129/biovar gravis database (Proteome Id: UP000002198) in UniProt
(www.uniprot/proteomes) and the Proteome Discoverer 1.4 program package (Thermo Fisher Scientific,
Bremen, Germany). As described by Schäfer and co-workers [18] theoretical masses for peptides were
generated by trypsin digestion with a maximum of two missed cleavages. Product ions were compared
to the measured spectra using the following parameters: carbamidomethyl modification on cysteine
was set as fixed and oxidation of methionine as dynamic modification. Mass tolerance was set to
10 ppm for survey scans and 0.6 Da for fragment mass measurements. For protein identification the
thresholds were set on 1% false discovery rate (FDR).
2.4. Label-Free Quantitative Protein Analysis
For protein quantification, three samples from the German and Indian vaccine as well as three single
vaccine doses from the Russian vaccine were prepared and analyzed by mass spectrometry. Based on
the total protein approach (TPA) method [19,20] we used the peak area for protein quantification [21,22].
The total protein content was defined as the sum of peptide intensities integrated over the elution
profile of each peptide and the amount of each identified protein was calculated as the ratio of their
intensity to the sum of all intensities in the sample [23]. Only peaks ranged from 2 × 107 up to
1011 where used for quantification [24]. In addition to the TPA-based quantification, the label-free
quantification method based on the Minora algorithm [25] and included in the Protein Discoverer 2.2
program package (Thermo Fisher Scientific, Bremen, Germany) was applied.
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2.5. Proteome Prediction of C. tetani
Cellular localization and the characteristics of C. tetani proteins identified in different samples of
vaccines were extracted from the UniProt database. Proteins with unknown localization were analyzed
by PSORTb v3.0.2 [26].
2.6. Prediction of Putative Antigens
A putative antigen function of proteins identified in the vaccine samples was determined using the
VaxiJen database (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) with a threshold of 0.4 [27].
2.7. Data Availability Statement
Mass spectrometry results have been deposited to the ProteomeXchange Consortium (http:
//proteomecentral.proteomexchange.org) via the PRIDE partner repository [28]. Data are available via
ProteomeXchange with identifier PXD009289.
3. Results
3.1. Mass Spectrometric Analysis of Tetanus Vaccines
3.1.1. Identification of Proteins
For protein analysis, the processed vaccine samples were subjected to mass spectrometry. Identified
peptides were analyzed with the Proteome Discoverer 1.4. For further investigations on protein
localization and function the UniProt database was used. In total 991 C. tetani proteins were identified
in all five analyzed vaccines (Table S1). Interestingly, the number of proteins identified in the different
samples varied significantly. The highest numbers were observed for the vaccines from India and
Russia with 662 and 627 proteins, respectively. The vaccine from Germany comprised 566 different
proteins, 427 proteins were found in the vaccine sample from Brazil and 369 proteins in the Bulgarian
vaccine. 206 unique proteins were present in all five analyzed vaccines (Figure 1).
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3.1.2. Protein Localization
While the number of proteins varied, the relative amount of secreted, membrane-located and
cytoplasmic proteins as well as proteins with no predicted localization was rather similar among the
different analyzed vaccines. Cytoplasmic proteins were 67.4 ± 3.3%, the major fraction in all vaccines
(Germany: 67.6%, India: 66.1%, Brazil: 67.3%, Bulgaria: 72.4%, Russia: 63.5% and the common 206
proteins: 71.9%), followed by 18.3 ± 2.6% membrane proteins (Germany: 18.3%, India: 18.6%, Brazil:
17.9%, Bulgaria: 14.5%, Russia: 22.0% and the common 206 proteins: 16.7%) and 12.1% ± 0.7 proteins
without predicted localization (Germany: 11.6%, India: 12.8%, Brazil: 12.6%, Bulgaria: 11.2%, Russia:
12.3% and the common 206 proteins: 8.6%), while secreted proteins were the smallest fraction with 2.2 ±
0.3% (Germany: 2.5%, India: 2.4%, Brazil: 2.2%, Bulgaria: 1.8%, Russia: 2.2% and the common proteins:
2.7%) (Figure 2). For 6.6 ± 1.0% of the proteins, two or more localizations were predicted (Germany:
6.3%, India: 5.7%, Brazil: 6.8%, Bulgaria: 5.6%, Russia: 8.1% and the common 206 proteins: 6.8%).
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respect to their predicted localization is show for the vaccines from diff rent c untries and for the
proteins common in all vaccines (grey: without predicted localization, gr en: cytoplasmic proteins,
blue: membrane proteins and black: secreted proteins). For proteins with more than one ann tated
localization, each localization was added to the corresponding group.
3.1.3. Bioinformatic Analysis of the 54 Common Unique Proteins in All Analyzed Vaccines
To characterize the immunological potential of C. t tani proteins identified as parts of the tetanus
toxoid vaccine, the proteins were analyzed in respect to the precence of signal peptides (SP) for protein
translocation, transmembrane (TM) domains and their potential antigenic properties (Figure 3). From a
total of 206 common proteins in all analyzed vaccines 23 proteins comprised a signal peptide (SP: 21,
SP/TM: 2) and 10 proteins contained a transmembrane domain (TM: 8, TM/SP: 2), while 175 proteins
comprised none of these motifs. Fifty-four proteins were predicted antigens based on a VaxiJen
database screening (Table 2).
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Table 2. Proteins with predicted antigenic potential identified in all five analyzed vaccines. The
localization was extracted from the UniProt database or predicted with Psortb v.3.0.2 (S: secreted, M:
membrane-localized, C: cytoplasm and U: unknown, without predicted localization).
UniProt ID Identifier Annotation Localization
P04958 CTC_p60 Tetanus toxin S, M, C
Q890P1 CTC_02598 50S ribosomal protein L2 U
Q890T2 CTC_02553 Thioredoxin M, C
Q890 × 6 CTC_02507 Tail-specific protease M, C
Q890Z2 CTC_02490 ATP-dependent 6-phosphofructokinase M, C
Q891M9 CTC_02340 Glycine betaine-binding protein M
Q891P2 CTC_02327 V-type ATP synthase beta chain 2 M, C
Q891Q6 CTC_02312 Conserved protein U
Q891U8 CTC_02265 UDP-glucose 6-dehydrogenase M, C
Q892B0 CTC_02196 Hydroxyacylglutathione hydrolase U
Q892H0 CTC_02129 Phage protein U
Q892K3 CTC_02093 N-acetylmuramoyl-L-alanine amidase/putative S-layer protein M
Q892P7 CTC_02047 Dihydrolipoyl dehydrogenase M, C
Q892V6 CTC_01980 Uncharacterized protein M
Q893B5 CTC_01913 Uncharacterized protein M
Q893R9 CTC_01741 Pyruvate-flavodoxin oxidoreductase U
Q893T5 CTC_01724 Flagellar hook-associated protein 1 S
Q894F4 CTC_01593 3-dehydroquinate dehydratase M
Q894P1 CTC_01495 Conserved protein U
Q894P7 CTC_01488 Fumarate reductase flavoprotein subunit M
Q894Q6 CTC_01479 Uncharacterized protein M, C
Q894Q7 CTC_01478 Putative histidine decarboxylase U
Q895A1 CTC_01379 Periplasmic transport protein, nickel or dipeptide transport M
Q895E4 CTC_01332 Transketolase U
Q895G9 CTC_01305 Uncharacterized protein U
Q895P6 CTC_01225 Serine/threonine protein kinase M
Q895R2 CTC_01209 Uncharacterized protein U
Q895T9 CTC_01178 NADH oxidase M, C
Q896G9 CTC_01036 Uncharacterized protein U
Q896I3 CTC_01021 Electron transport complex subunit G M
Q896J5 CTC_01009 Conserved protein, putative N-acetylmuramoyl-L-alanine amidase M
Q896U1 CTC_00907 D-ribose-binding periplasmic protein U
Q896W4 CTC_00882 Carboxyl-terminal protease M, C
Q896W8 CTC_00878 50S ribosomal protein L25 U
Q896Y3 CTC_00860 D-galactose-binding periplasmic protein U
Q896Y6 CTC_00856 Uncharacterized protein M, C
Q897C9 CTC_00811 Fumarate reductase flavoprotein subunit M
Q897E8 CTC_00792 Conserved protein M
Q897G1 CTC_00777 Putative surface/cell-adhesion protein U
Q897G4 CTC_00774 Putative surface/cell-adhesion protein M
Q897G6 CTC_00771 Putative surface/cell-adhesion protein M
Q897G7 CTC_00770 Putative surface/cell-adhesion protein, big2 domain U
Q897G8 CTC_00769 Putative surface/cell-adhesion protein M, C
Q897I6 CTC_00749 Putative surface/cell-adhesion protein, multiple big2 domain M
Q897I8 CTC_00747 Putative surface/cell-adhesion protein, multiple big2 domain M
Q897P1 CTC_00691 Putative S-layer protein/internalin A-like/N-acetylmuramoyl-L-alanine amidase M
Q897Q0 CTC_00681 Conserved protein M
Q897W0 CTC_00612 Serine protease S
Q898E1 CTC_00519 Zink-carboxypeptidase U
Q898I5 CTC_00465 Putative S-layer protein M
Q898I7 CTC_00462 Putative S-layer protein/N-acetylmuramoyl-L-alanine amidase M
Q898R0 CTC_00382 Enolase S
Q898S3 CTC_00369 Membrane lipoprotein tmpC M
Q899E7 CTC_00234 Putative cell wall hydrolase S
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3.1.4. Quantification of Proteins
he three vaccines with the highest number of differe t proteins were chosen for more detailed
characteri i n of the relative amounts of distinct proteins. In a first approach, DT vaccines were
analyzed in respe t to their protein content origi ati g from C. tetani and C. diphtheriae. In all cases, the
major part of the proteins of the DT vaccines analyzed were proteins from tetanus toxoid preparations,
while C. diphtheriae proteins were present in much lower abundance, which corresponds to the different
international units combined in the DT vaccines (see Table 1).
The vaccine from Germany contained 94.3 ± 0.9% proteins from C. tetani, the vaccine from India
88.1 ± 5.8% and the vaccine from Russia 85.1 ± 4.1% when analyzed with the TPA-based method
described by [19–22] (Figure 4a). Proteins from C. iphtheriae reached 5.7 ± 0.88% in the German vaccine
samples, 11.9 ± 5.8% in the Indian samples and 14.9 ± 0.1% i the Russian vaccine. When the Proteome
Discoverer 2.2 program package based on the minora algorithm [25] was applied, a similar distribution
was observed. In the German vaccine 95.5 ± 0.5% C. tetani and 4.5 ± 0.5% C. diphtheriae proteins were
found, in the Indian vaccine 93.1 ± 1.3% C. tetani and 6.9 ± 1.3% C. diphtheriae proteins were observed
and in the Russian vaccine 90.5 ± 0.1% C. tetani and 9.5 ± 0.1% C. diphtheriae proteins were detected
(Figure 4b).
As next step, the relative amount of tetanus neurotoxin (TeNT) in the tetanus toxoid preparations
was determined. TeNT represented 48.2 ± 12.2% in th G rman vaccine, 43.7 ± 5.8% in the vaccine
from India and only 17.2 ± 3.0% in the vaccine from Russia when analyzed with the TPA-based method
(Figure 5a). When the Proteome Discoverer software package 2.2 was used, TeNT reached 72.9 ± 8.4%
in the German vaccine, 72.9 ± 2.8% in the Indian vaccine and 29.4 ± 1.1% in the vaccine from Russia
when analyzed with the TPA-based method (Figure 5b).
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M 
Q897Q0 CTC_00681 Conserved protein  M 
Q897W0 CTC_00612 Serine protease  S 
Q898E1 CTC_00519 Zink-carboxypeptidase  U 
Q898I5 CTC_00465 Putative S-layer protein  M 
Q898I7 CTC_00462 Putative S-layer protein/N-acetylmuramoyl-L-alanine amidase  M 
Q898R0 CTC_00382 Enolase  S 
Q898S3 CTC_00369 Membrane lipoprotein tmpC  M 
Q899E7 CTC_00234 Putative cell wall hydrolase  S 
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88.1 ± 5.8% and the vaccine from Russia 85.1 ± 4.1% when analyzed with the TPA-based method 
described by [19–22] (Figure 4a). Proteins from C. diphtheriae reached 5.7 ± 0.88% in the German 
vaccine samples, 11.9 ± 5.8% in the Indian samples and 14.9 ± 0.1% in the Russian vaccine. When the 
Proteome Discoverer 2.2 program package based on the minora algorithm [25] was applied, a similar 
distribution was observed. In the German vaccine 95.5 ± 0.5% C. tetani and 4.5 ± 0.5% C. diphtheriae 
proteins were found, in the Indian vaccine 93.1 ± 1.3% C. tetani and 6.9 ± 1.3% C. diphtheriae proteins 
were observed and in the Russian vaccine 90.5 ± 0.1% C. tetani and 9.5 ± 0.1% C. diphtheriae proteins 
were detected (Figure 4b). 
 
Figure 4. Relative protein amounts in DT vaccines. Comparison of relative protein amounts from C.
tetani (blue) and C. diphtheriae (grey) in the vaccines from Germany, India and Russia. (a) Analysis
by the TPA-based method using the area under the peak. Only proteins with peptides in in a range
from 2 × 107 to 1011 were considered for calculation. (b) Analysis with the Proteome discoverer 2.2
program package.
Taken together, with this method higher relative amounts of TeNT were detected; however, in all
cases the Russian vaccine contained the lowest amount of TeNT. Since the toxoid was adjusted in form
of flocculation units [13,14], this meant that the Russian toxoid was the most immunologically active in
this comparison.
When the protein content from C. tetani in the Russian vaccine was analyzed in more detail using
the TPA-based method, the TeNT represented only 17.2 ± 3.0% of all C. tetani proteins, while the
putative S-layer protein/N-acetylmuramoyl-L-alanine amidase CTC_00462 reached 16.7 ± 0.8% of the
protein content, the putative S-layer protein CTC_00465 9.6 ± 1.1% and the remaining proteins summed
up to 56.5 ± 3.0% (Figure 6a). Also in this case, the general tendency of protein distribution was similar
when the Proteome Discoverer software package was used. In this case the TeNT reached 29.4 ±
1.1% of all C. tetani proteins, while the putative S (surface)-layer protein/N-acetylmuramoyl-L-alanine
amidase CTC_00462 reached 17.3 ± 0.3%, the putative S-layer protein CTC_00465 13.5 ± 0.4% and the
remaining proteins 39.8 ± 1.1% (Figure 6b).
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4. Discussion
Proteomic data are scarce for C. tetani and only a few proteins have been identified in proteome
studies up to now [29]. In frame of this study, we were able to identify 991 different proteins of C. tetani
as components of tetanus toxoid vaccines. In addition, we found a highly variable number of proteins
depending on the studied vaccines, which may indicate that different companies use different protocols
for tetanus toxoid production.
Independent of the number of detected proteins and the protein quantification method used, the
main component of all vaccines was tetanus neurotoxin. The high number of predicted cytoplasmic
proteins found in this study, 64% of the total identified proteins, may be explained by cell lysis of
bacteria, which leads to a release and accumulation of especially highly abundant and stable proteins
such as components of glycolysis, pentose phosphate pathway, tricarboxylic acids cycle and protein
turnover into the supernatant. Alternatively, nonclassical transporters or nonspecific leakage or release
by exosomes was discussed for these group of proteins [5]. Shearing forces may be another source of
membrane-associated proteins, resulting for example from stirring during cultivation.
From the 206 proteins present in all samples, 54 showed immunogenic potential. Especially
antibodies directed against surface-exposed proteins such ABC (ATP-binding cassette) transporter
components (CTC_02340, CTC_01379, CTC_00907, CTC_00860), putative S-layer proteins (CTC_02093,
CTC_00691, CTC_00465, CTC_00462), flagellar components (CTC_01724) and putative adhesins
(CTC_00777, CTC_00774, CTC_00771, CTC_00770, CTC_00769, CTC_00749, CTC_00747) may have an
influence on host colonization by the pathogen. This may also be true, when antibodies against putative
virulence factors such as proteases are induced (CTC_02507, CTC_01225, CTC_00882, CTC_00612,
CTC_00519). In addition, enolase (CTC_00382) was found among the 206 proteins observed in all
studied vaccines, was predicted to have immunogenic properties. This enzyme was identified earlier
as one of a group of cross-reactive proteins from C. perfringens, which may provide protection against
C. tetani [29].
In summary, besides the tetanus neurotoxin, which contributes between 14 and 76% to the total C.
tetani protein content depending on the tetanus vaccine sample and the protein quantification method
used, a high number of other C. tetani proteins were detected, which may contribute at least partially
to a protection against C. tetani infection supporting the function of the vaccine against the devasting
effects of the tetanus toxin indirectly.
Interestingly, Clostridium botulinum toxoid vaccination in Danish cows did not only reduce
botulinum neurotoxin in cattle feces, but also the number of C. botulinum spores. This observation
may support the idea that toxoid preparation may also protect against infection with pathogenic
bacteria [30].
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5. Conclusions
DT vaccines consist of about 20%C. diphtheriae and about 80%C. tetaniproteins. Tetanus neurotoxin
is a major protein in toxoid preparations; however, similar amounts of putative S-layer proteins are
found as well. These and other proteins found may contribute to protection against C. tetani infection.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-7382/7/2/15/s1, Table
S1: C. tetani proteins identified in vaccine samples analyzed. Common proteins shaded in grey.
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